Medizinische Universität Graz - Research portal
Selected Publication:
Koestenberger, M; Gallistl, S; Cvirn, G; Roschitz, B; Petritsch, M; Leschnik, B; Muntean, W.
Combined effects of eptifibatide and anticoagulants: differences between LMWH and UH or rH in thrombin generation inhibition but not in platelet aggregation inhibition.
Thromb Haemost. 2002; 88(6):1012-1019
Doi: 10.1267/th02121012
Web of Science
PubMed
FullText
FullText_MUG
Google Scholar
- Leading authors Med Uni Graz
- Koestenberger Martin
- Co-authors Med Uni Graz
- Acham-Roschitz Birgit
- Cvirn Gerhard
- Gallistl Siegfried
- Leschnik Bettina
- Muntean Eugen
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- Aim of our study was to investigate effects of eptifibatide and anticoagulants on platelet aggregation and thrombin generation under low and high coagulant challenge in tissue factor-activated platelet rich plasma using a model allowing simultaneous determination of the time course of platelet aggregation and thrombin generation. Eptifibatide exerted a dose-dependent anti-aggregating effect under both high and significantly stronger under low coagulant challenge. Combination of eptifibatide and anticoagulants resulted in significant additive prolongation of the lag phase until the onset of platelet aggregation, more pronounced under low coagulant challenge. Under high, but not under low coagulant challenge combination of eptifibatide and anticoagulants had a significant synergistic inhibitory effect on platelet aggregation. Under low coagulant challenge combination of eptifibatide with LMWH, but not with UH, or rH, resulted in significantly reduced thrombin potential, F 1+2 generation, and FXa formation compared to measurements in the absence of eptifibatide. We demonstrate a synergistic effect of eptifibatide and anticoagulants on platelet aggregation inhibition and an additional inhibitory effect of LMWH and eptifibatide on thrombin generation. Our results support the notion that combination of eptifibatide and anticoagulants might be beneficial in atherosclerotic disease to palliate the thrombogenic potency of ruptured atherosclerotic plaques.
- Find related publications in this database (using NLM MeSH Indexing)
- Anticoagulants - administration and dosage
- Arteriosclerosis - blood
- Drug Synergism - blood
- Factor Xa - biosynthesis
- Heparin - administration and dosage
- Heparin, Low-Molecular-Weight - administration and dosage
- Hirudins - administration and dosage
- Humans - administration and dosage
- Peptides - administration and dosage
- Platelet Aggregation - drug effects
- Platelet Aggregation Inhibitors - administration and dosage
- Recombinant Proteins - administration and dosage
- Thrombin - biosynthesis
- Thrombosis - prevention and control
- Find related publications in this database (Keywords)
- simultaneous determination
- thrombin generation
- platelet aggregation
- eptifibatide
- LMWH